SCHEMBL361852

SCHEMBL361852

CC1(C)OC(=O)c2ccccc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 1/20 0.53
GOPC Q9HD26 1/20 0.53
NPSR1 Q6W5P4 7/20 0.47
LMNA P02545 4/20 0.47
MAPT P10636 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
POLB P06746 3/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
TDP1 Q9NUW8 3/20 0.47
CYP3A4 P08684 3/20 0.47
GPR55 Q9Y2T6 2/20 0.47
ALDH1A1 P00352 1/20 0.47
ESR1 P03372 1/20 0.47
TP53 P04637 1/20 0.47
TYMS P04818 1/20 0.47
ALOX15 P16050 1/20 0.47
TSHR P16473 1/20 0.47
ESR2 Q92731 1/20 0.47
HSD17B10 Q99714 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29672587 1.00 CFTR (0.53) CFTRGOPCNPSR1LMNAMAPT
SCHEMBL31322061 0.91 CFTR (0.46) CFTRGOPCNPSR1LMNAMAPT
SCHEMBL31267314 0.78 CFTR (0.50) CFTRGOPCNPSR1LMNAMAPT
SCHEMBL28995190 0.78 CFTR (0.50) CFTRGOPCNPSR1LMNAMAPT
SCHEMBL7697104 0.78 CFTR (0.50) CFTRGOPCNPSR1LMNAMAPT
SCHEMBL12218620 0.77 CFTR (0.35) CFTRGOPCNPSR1LMNAMAPT
SCHEMBL24187212 0.77 ALDH1A1 (0.44) CFTRGOPCLMNAMAPTSMN1; SMN2
SCHEMBL22343694 0.77 CFTR (0.48) CFTRGOPCNPSR1LMNAMAPT
SCHEMBL9787743 0.76 CFTR (0.57) CFTRGOPCNPSR1LMNAMAPT
SCHEMBL21663069 0.76 PGR (0.40) CFTRGOPCNPSR1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 437 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117776886-A Preparation method of melitracen hydrochloride intermediate 广东赛烽医药科技有限公司 2024-03-29 CN claimed
CN-111527084-B Isofuranone compounds useful as HPK1 inhibitors 百时美施贵宝公司 2023-07-18 CN claimed
EP-0397474-A2 Photosensitive composition KABUSHIKI KAISHA TOSHIBA (JP) 1990-11-14 EP claimed
JP-7206843-A None JP disclosed
US-20260015340-A1 COMPOUND INCLUDING 2,4-DIAMINOPYRIDINE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2026-01-15 US disclosed
US-20250381202-A1 PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY ZOUNEK ALEX (DE) 2025-12-18 US disclosed
EP-4520757-A1 COMPOUND INCLUDING 2,4-DIAMINOPYRIDINE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER Korea Research Institute of Chemical Technology (KR) 2025-03-12 EP disclosed
US-20240238724-A1 METHODS AND SYSTEMS FOR CONTROLLING EMISSIONS FROM WOOD DRYING PROCESSES JPMORGAN CHASE BANK, N.A. 2024-07-18 US disclosed
WO-2024128160-A1 CURABLE COMPOSITION, CURED BODY, LAMINATE, LENS, AND SPECTACLES 株式会社トクヤマ 2024-06-20 WO disclosed
WO-2024128158-A1 CURABLE COMPOSITION, CURED BODY, LAMINATE, LENS, AND SPECTACLES 株式会社トクヤマ 2024-06-20 WO disclosed
WO-2024128159-A1 CURABLE COMPOSITION, CURED BODY, LAMINATE, LENS, AND SPECTACLES 株式会社トクヤマ 2024-06-20 WO disclosed
US-7169941-B2 Photochromic composition TOKUYAMA CORPORATION (JP) 2007-01-30 US disclosed
US-7060844-B2 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-06-13 US disclosed
US-20060004084-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-01-05 US disclosed
EP-1490356-A1 (3Z)-3-(3-HYDRO-ISOBENZOFURAN-1-YLIDENE)-1,3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS Allergan, Inc. (US) 2004-12-29 EP disclosed
US-20040019098-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2004-01-29 US disclosed
WO-2003084951-A1 (3Z) -3-(3-HYDRO-ISOBENZOFURAN-1-YLIDENE)-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS ALLERGAN, INC. (US) 2003-10-16 WO disclosed
JP-H07206843-A VASODILATOR KAO CORP 1995-08-08 JP disclosed
US-5100768-A Photoresists for integrated circuits, polyvinyl phenol and nitrogen containing heterocycle KABUSHIKI KAISHA TOSHIBA (JP) 1992-03-31 US disclosed
EP-0397474-A2 Photosensitive composition KABUSHIKI KAISHA TOSHIBA (JP) 1990-11-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250381202-A1 PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY KIT, CTSL, PAICS CFTR 2920/4885GOPC 4083/4885NPSR1 3724/4885
US-20060004084-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors CDK2, ERBB2, MAP3K3 CFTR 4823/4885GOPC 2643/4885NPSR1 2444/4885
US-20040019098-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors CDK2, ERBB2, MAP3K3 CFTR 4825/4885GOPC 2660/4885NPSR1 2350/4885
US-20260015340-A1 COMPOUND INCLUDING 2,4-DIAMINOPYRIDINE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER MINK1, HK1, PDK3 CFTR 867/4885GOPC 1288/4885NPSR1 4429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.